Hummingbird Bioscience to Speak at 2021 Virtual Symposium: VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
HOUSTON and SINGAPORE, June 9, 2021 /PRNewswire/ Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company, Novogene Co., Ltd. ( Novogene ). The partnership will leverage Novogene s strong molecular diagnostics capabilities to expand patient identification through Next Generation Sequencing, NGS, testing in China to support the development of Hummingbird Bioscience s investigational drug candidate HMBD-001, an anti-HER3 antibody that will be evaluated for treatment of multiple tumor types, including NRG1-fusion driven cancers. HMBD-001 is expected to enter phase 1 clinical trials later this year.
/PRNewswire/ Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets.
Share:
COPENHAGEN, Denmark, 18 May 2021 /PRNewswire/ Novo Holdings today announced that it has led the oversubscribed US$125 million Series C financing in Hummingbird Bioscience (Hummingbird), an innovative clinical-stage biotech company focused on developing precision therapies against difficult-to-drug targets to improve treatment outcomes. This is one of the first investments in a privately-held Asian biotech company by Novo Holdings. Novo Holdings recently established an Asian life sciences investment platform in Singapore, Novo Holdings Equity Asia Pte. Ltd. ( Novo Holdings Asia ). Kenneth Harrison, Partner, Novo Ventures, will join Hummingbird s board of directors.
Hummingbird, headquartered in Singapore and the US, is developing a broad pipeline of first- and best-in-class drug candidates across multiple indications for the treatment of cancer. Proceeds from the financing will be used to advance the clinical development of Hummingbird s lead assets including HMBD-001,
SG biotech startup Hummingbird Bioscience bags $125m Series C funding
Antibody visual sourced from Hummingbird s website
May 18, 2021
Singapore-based biotech startup Hummingbird Bioscience has announced raising $125 million in a Series C funding round led by life science investor Novo Holdings.
A syndicate of international biotech investors also participated in the funding round, including Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital, and others.
The biotech startup, which raised $25 million in an extended Series B round in May 2020, said it will use the fresh funding to advance the clinical development of its lead assets, including the antibody HMBD-001, which targets HER3, a cell surface protein associated with several cancers, including colorectal, gastric, and lung.